Deerfield Management Company, L.P.: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1009258) · Explore on the interactive board
Deerfield Management Company, L.P. disclosed 82 US equity positions worth $9.6bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is NUVALENT INC at 22.2% of the reported book, followed by BROOKDALE SR LIVING INC, RVMD. The top ten holdings are 53.2% of the book, and the portfolio behaves like about 15 equal-weight positions. Versus the prior filing it opened 13 new positions, added to 13, reduced 12 and exited 13. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Deerfield Management Company, L.P. own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 13 new, 13 added, 12 reduced, 13 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | NUVALENT INC | 22.2% | $2.1bn | 17,248,450 | 0% | held | |
| 2 | BROOKDALE SR LIVING INC | 6.1% | $585.7m | 306,885,000 | 0% | held | |
| 3 | RVMD REVOLUTION MEDICINES INC | Healthcare | 4.7% | $448.0m | 2,392,000 | 4% | added |
| 4 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 3.4% | $322.5m | 963,351 | 0% | held |
| 5 | VTRS VIATRIS INC | Healthcare | 3.3% | $320.9m | 20,206,170 | 0% | held |
| 6 | CNC CENTENE CORP DEL | Healthcare | 3.3% | $314.6m | 4,901,000 | -17% | reduced |
| 7 | REVOLUTION MEDICINES INC | 2.6% | $251.7m | 200,000,000 | – | new | |
| 8 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 2.6% | $247.6m | 457,000 | 0% | held |
| 9 | ARROWHEAD PHARMACEUTICALS IN | 2.5% | $240.5m | 200,000,000 | 0% | held | |
| 10 | LEGN LEGEND BIOTECH CORP | Healthcare | 2.5% | $235.0m | 8,137,638 | 6% | added |
| 11 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.0% | $193.7m | 5,006,104 | -45% | reduced |
| 12 | GMAB GENMAB A/S | Healthcare | 2.0% | $188.6m | 6,865,000 | 179% | added |
| 13 | BKD BROOKDALE SR LIVING INC | Healthcare | 2.0% | $187.2m | 11,637,032 | 0% | held |
| 14 | VERA VERA THERAPEUTICS INC | Healthcare | 1.8% | $168.1m | 3,916,400 | 5% | added |
| 15 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 1.6% | $157.0m | 1,979,669 | 0% | held |
| 16 | CELC CELCUITY INC | Healthcare | 1.6% | $151.8m | 1,451,014 | -15% | reduced |
| 17 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 1.6% | $151.0m | 15,096,403 | 0% | held |
| 18 | NEWAMSTERDAM PHARMA COMPANY | 1.5% | $144.5m | 4,264,789 | 0% | held | |
| 19 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 1.4% | $133.5m | 4,520,000 | 0% | held |
| 20 | TNGX TANGO THERAPEUTICS INC | Healthcare | 1.4% | $131.0m | 4,190,611 | 1% | added |
| 21 | AHCO ADAPTHEALTH CORP | Healthcare | 1.2% | $119.6m | 11,477,730 | 0% | held |
| 22 | PHVS PHARVARIS N V | Healthcare | 1.2% | $116.7m | 3,376,042 | 8% | added |
| 23 | CELCUITY INC | 1.2% | $113.8m | 100,000,000 | – | new | |
| 24 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.2% | $113.2m | 1,389,055 | -12% | reduced |
| 25 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.1% | $109.7m | 1,125,313 | 10% | added |
| 26 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 1.1% | $108.6m | 35,606,974 | 0% | held |
| 27 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.1% | $106.8m | 3,958,000 | – | new |
| 28 | ALIGNMENT HEALTHCARE INC | 1.1% | $103.8m | 61,000,000 | 0% | held | |
| 29 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.1% | $101.2m | 2,714,503 | 77% | added |
| 30 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.0% | $97.5m | 1,615,696 | 0% | held |
| 31 | IONIS PHARMACEUTICALS INC | 1.0% | $93.1m | 60,000,000 | 0% | held | |
| 32 | SVRA SAVARA INC | Healthcare | 0.9% | $83.6m | 13,569,000 | 0% | held |
| 33 | LNTH LANTHEUS HLDGS INC | Healthcare | 0.9% | $83.5m | 752,999 | -9% | reduced |
| 34 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.9% | $82.6m | 3,779,900 | 0% | held |
| 35 | ZENAS BIOPHARMA INC | 0.8% | $80.3m | 67,200,000 | 3% | added | |
| 36 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 0.8% | $76.3m | 1,332,836 | 57% | added |
| 37 | PFE PFIZER INC | Healthcare | 0.8% | $73.2m | 3,040,000 | 0% | held |
| 38 | INDV INDIVIOR PHARMACEUTICALS INC | Healthcare | 0.7% | $67.7m | 1,648,895 | -47% | reduced |
| 39 | BIO BIO RAD LABS INC | Healthcare | 0.7% | $66.4m | 226,070 | 0% | held |
| 40 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.6% | $60.1m | 7,503,812 | 0% | held |
| 41 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.6% | $59.7m | 1,823,500 | 0% | held |
| 42 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.6% | $58.3m | 1,086,000 | 41% | added |
| 43 | NVST ENVISTA HOLDINGS CORPORATION | Healthcare | 0.6% | $58.2m | 2,210,100 | 0% | held |
| 44 | INSP INSPIRE MED SYS INC | Healthcare | 0.6% | $57.9m | 1,296,862 | -52% | reduced |
| 45 | CDNA CAREDX INC | Healthcare | 0.6% | $56.9m | 1,997,618 | -9% | reduced |
| 46 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 0.6% | $56.1m | 1,315,000 | – | new |
| 47 | BLTE BELITE BIO INC | Healthcare | 0.6% | $55.0m | 357,199 | 17% | added |
| 48 | PARABILIS MEDICINES INC | 0.5% | $51.5m | 1,880,704 | – | new | |
| 49 | CERT CERTARA INC | Healthcare | 0.5% | $49.2m | 7,512,928 | -4% | reduced |
| 50 | IRON DISC MEDICINE INC | Healthcare | 0.5% | $48.1m | 657,000 | 0% | held |
What did Deerfield Management Company, L.P. sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| MIRM MIRUM PHARMACEUTICALS INC | 33.9% | $209.4m |
| CATALYST PHARMACEUTICALS INC | 15.8% | $97.6m |
| NBIX NEUROCRINE BIOSCIENCES INC | 13.0% | $80.4m |
| DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 12.9% | $79.8m |
| ENHABIT INC | 10.8% | $66.9m |
| KYMR KYMERA THERAPEUTICS INC | 7.6% | $46.7m |
| CMPX COMPASS THERAPEUTICS INC | 3.1% | $19.1m |
| TSHA TAYSHA GENE THERAPIES INC | 2.0% | $12.2m |
| CGEM CULLINAN THERAPEUTICS INC | 0.9% | $5.5m |
| BIOMX INC | 0.1% | $492.8k |
| MANE VERADERMICS INC | 0.1% | $315.8k |
| QUANTUM SI INC | 0.0% | $36.2k |
| MYGN MYRIAD GENETICS INC | 0.0% | $2.3k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 57.3% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Deerfield Management Company, L.P.'s portfolio?
Across every quarter Deerfield Management Company, L.P. has filed, its median largest position is 21.5% of the book and its median top-ten weight is 52.0%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 12.0 completed holding spells, the median lasted 1.0 quarters; 82.0 positions are still open and their final length is unknown.